Bone Marrow MSCs: A Long-Read Primer

Bone marrow mesenchymal stromal cells occupy an uneasy middle position in the regenerative-medicine vocabulary — older than adipose SVF as a clinical concept, narrower than the marketing copy implies, central to a literature that is still, quietly, rewriting itself. The cells are recovered from the patient's posterior iliac crest by a brief aspiration; the harvest takes minutes; the biology takes a career to read. 慢慢嚟, an older lab head told me last winter at a hotel in Yeoksam, his way of saying the field rewards patience. He was right. What follows is a long-read primer — what BM-MSCs are, where they come from, what the harvest involves, and what the data does and does not support. The hedging is the only honest register here.

What bone marrow MSCs are — definition and lineage

Bone marrow mesenchymal stromal cells are a heterogeneous population of plastic-adherent, fibroblast-like cells recovered from the bone marrow stroma — the cellular scaffold within the marrow cavity that supports haematopoiesis but is not itself haematopoietic. The International Society for Cell & Gene Therapy's 2006 minimal criteria — still the operative reference — define MSCs by three characteristics: plastic adherence in standard culture conditions; expression of CD73, CD90, and CD105 surface markers in the absence of CD34, CD45, CD11b, CD14, CD19, and HLA-DR; and the capacity to differentiate, under appropriate inductive conditions, into osteoblasts, adipocytes, and chondroblasts in vitro. The cells were originally described by Friedenstein and colleagues in the 1970s as colony-forming-unit fibroblasts; the term mesenchymal stem cell was popularised in the 1990s; the more careful contemporary literature increasingly favours stromal cell over stem cell, on the grounds that the stem-cell criteria — long-term self-renewal, multilineage in vivo differentiation — are met less reliably than the marketing language suggests. The vocabulary, in other words, is settling. The cells are real; the claims one makes about them require care. The vocabulary distinction matters at the consultation table, and not only as an editorial nicety. A patient who arrives expecting a stem-cell injection in the lay sense — multipotent cells that will integrate into damaged tissue and become the missing material — is operating with a model the field has, quietly, moved past. A patient who arrives expecting a stromal cell preparation that will, for a transient residence in the injection site, secrete a complex paracrine signal and recruit the body's own resident cells to do the repair work, is operating with a model the contemporary literature recognises. The expectation-setting is not a small matter. It changes the time course one anticipates, the response one accepts as a result, and the conversation one has at the three-month and six-month follow-up. Reputable consultations spend time, deliberately, on the vocabulary. The rooms that skip this step tend to disappoint, regardless of the technical quality of the procedure that follows.

The harvest — what the iliac crest aspiration actually involves

The harvest procedure is, in clinical practice, briefer and less involved than the consent paperwork can make it appear — and the paperwork is no less important for that. The patient is positioned prone or in the lateral decubitus position; the posterior iliac crest is identified by palpation; the harvest field is prepared with chlorhexidine and draped sterile. Local anaesthesia is infiltrated through the skin, the subcutaneous tissue, and the periosteum; intravenous sedation is offered in some clinics, declined by patients in others, and the choice is genuinely a comfort rather than a clinical question for most candidates. A specialised aspiration trocar is then advanced into the marrow cavity, and small-volume aspirates — typically five to ten millilitres per draw, repeated two to four times across slightly different trajectories within the iliac wing — are withdrawn into anticoagulated syringes. The total marrow volume aspirated runs from twenty to sixty millilitres in the regenerative protocols, well below the volumes associated with allogeneic donation for haematological indications. The whole field-prep-to-completion sequence sits within a forty-five to ninety-minute window. Patients report a deep, brief, pressure-like sensation during each aspirate — never described as pain in the conventional sense, more as the sound of pressure changing — followed by mild soreness at the harvest site for three to seven days. The procedure is, in practical terms, less involved than the dental extraction many patients describe as their reference point for clinical discomfort.

From aspirate to product — concentrate versus culture-expanded

Once the marrow is aspirated, two distinct downstream pathways diverge — and the choice between them is the most consequential decision in any BM-MSC protocol. The first pathway, sometimes called bone marrow aspirate concentrate or BMAC, is a same-session preparation: the aspirate is centrifuged, the buffy-coat layer (containing the mesenchymal and haematopoietic fractions) is recovered, washed, and reinjected within the same clinical visit. The cells received are the cells provided; there is no expansion, no characterisation, no time. The second pathway is culture expansion: the aspirate is processed in a GMP-compliant cell-therapy laboratory, the plastic-adherent fraction is selected over the first passage, and the cells are expanded across two to four weeks under defined media conditions before being cryopreserved or shipped fresh for reinjection. The expanded product is more characterised — flow cytometry, viability counts, identity assays — and contains substantially more MSCs by absolute number, often by two or three orders of magnitude over what a same-session BMAC delivers. The trade-off is regulatory. Culture-expanded MSCs are classified as a cell-therapy product in many jurisdictions, with attendant manufacturing, traceability, and clinical-trial requirements that BMAC does not trigger. Korea operates within the more permissive end of the East Asian regulatory spectrum for autologous cell therapy, but the framework is genuinely active and a careful clinic discloses which pathway the patient is receiving. The conversation is the place where this question is answered. If the answer is unclear, it is unclear for a reason. The practical implications of the BMAC-versus-expansion decision extend beyond the regulatory file. A same-session BMAC procedure delivers a heterogeneous mixed-population product — MSCs, haematopoietic stem cells, immune cells, platelets, plasma — whose biology may, paradoxically, be more useful than a purified population in some niches. The mixed signal of a marrow aspirate is, after all, the signal evolution selected for; the expanded MSC monolayer is a derivative simplification. The expansion pathway, by contrast, delivers a much higher absolute MSC count under controlled identity and potency parameters, which the more rigorous orthopaedic and immunological indications increasingly favour. Neither is universally better. The choice tracks the indication, the operator's judgment, the patient's logistics — a culture pathway requires a return visit two to four weeks later — and, candidly, the regulatory comfort of the receiving clinic. The rooms that volunteer all of this in the first thirty minutes of the consultation are the rooms one returns to.

What the cells are believed to do — paracrine biology

The contemporary working model of BM-MSC mechanism — and this has shifted notably in the past decade — treats the cells less as direct tissue-replacement agents and more as paracrine modulators of a damaged niche. The early literature, in the 1990s and 2000s, framed MSCs as multipotent stem cells that homed to the injury site and differentiated into the missing tissue. The contemporary literature, summarised in a 2016 update in Cell Transplantation that remains influential, frames the cells as transient secretory units: they arrive, secrete a complex paracrine signal — growth factors, anti-inflammatory cytokines, exosomes carrying microRNAs, immunomodulatory mediators — and either die or are cleared within days to weeks. The therapeutic effect, where there is one, is attributed to the local environment they create rather than to the cells themselves persisting in the tissue. This shift has practical consequences for how one interprets the indications. Conditions with a strong inflammatory or microvascular component — knee osteoarthritis, certain non-healing wounds, graft-versus-host disease in the haematological setting — have been the more reproducible BM-MSC indications, because the paracrine model fits the disease biology. Conditions that require structural tissue replacement — frank cartilage defects, large bone gaps, neurological repair — have generated more variable data, because the structural model the marketing copy still uses is not what the cells actually do. Patients report symptom modification — pain, range of motion, swelling — more reliably than they report anatomical reconstruction. Studies suggest the effect is dose-dependent, niche-dependent, and protocol-dependent in ways the field is still characterising.

How BM-MSCs compare to adjacent regenerative preparations

BM-MSCs are not the only autologous cell preparation on offer in a Seoul consultation, and the differences between the categories are larger than the consumer literature suggests. The table below — categorically, not as a ranking — places BM-MSCs alongside the adjacent options. The choice between categories is a clinical decision rather than a marketing one, and the indication, the patient's anatomy, and the operator's familiarity with each pathway weigh more heavily than any cross-category preference.

Indications under active investigation — what the trials are testing

The indication pipeline is broader than the consumer-facing copy suggests, and the registered trial landscape is the most reliable place to read it. A search of the United States National Library of Medicine's [ClinicalTrials.gov](https://clinicaltrials.gov/) registry for bone marrow mesenchymal stromal cells returns several hundred registered studies across orthopaedic, immunological, cardiovascular, neurological, and wound-care indications — including knee osteoarthritis, degenerative disc disease, refractory graft-versus-host disease, ischaemic cardiomyopathy, multiple sclerosis, Crohn's disease perianal fistulae, and post-radiation tissue injury. The aesthetic indications occupy a smaller fraction of the registered work for BM-MSCs than for adipose SVF — a function of the harvest involvement, which makes BM the less natural starting point for cosmetic indications, and of the cell biology, which makes BM-MSCs the more natural starting point for inflammation-driven and immune-modulated conditions. The candid editorial position is that BM-MSCs are, on balance, more often chosen for orthopaedic and immunological indications than for aesthetic ones, and that the marketing copy that elides this distinction is not serving the candidate patient. A careful Seoul consultation will route an aesthetic indication toward SVF or adipose-derived approaches in most cases, and reserve BM-MSCs for the indications in which the harvest investment is justified by the disease biology. The Korean Ministry of Health and Welfare's [foreign-patient registration framework](https://www.mohw.go.kr/eng/) provides the regulatory baseline; the indication choice sits with the operator and the patient.

Risks, contraindications, and the long-tail unknowns

The acute risk profile of an autologous BM-MSC procedure tracks the harvest more than the reinjection — and the harvest risks are well-characterised. Local complications include bruising, brief haematoma, and rare infection at the iliac harvest site; systemic complications from a small-volume aspirate are exceedingly uncommon in the published series. Patients report deep soreness at the posterior iliac crest for three to seven days, manageable with paracetamol; ambulation is unrestricted from the same evening. Reinjection-site sequelae depend on the target indication and are typically minor and self-limited. The contraindications mirror those for other autologous regenerative procedures: active or recent malignancy, uncontrolled autoimmune disease, active infection at the harvest or injection site, current pregnancy or lactation, and bleeding disorders or anticoagulation that cannot be safely paused. The long-tail unknowns are honest unknowns. Follow-up data on BM-MSC preparations rarely extends past five to seven years in published cohorts, and the heterogeneity of preparation protocols — same-session versus culture-expanded, dose, route, adjunct — makes meta-analysis genuinely difficult. The honest editorial summary is that BM-MSCs are a clinically established cell preparation with a favourable acute safety profile, an evolving evidence base for several indications, and a marketing language that occasionally outruns the data. The room one returns to is the one that volunteers the limitations as readily as the strengths. One arrives, sits down, and listens for the hedging. The hedging is the signal. A practical note on choosing the operator. The harvest itself is a procedure most experienced regenerative-medicine specialists have performed many times; the differentiator is rarely technical skill at the iliac aspiration step. The differentiator is the surrounding apparatus — the consultation cadence, the cell-counting infrastructure, the GMP partnership for culture-expansion cases, the follow-up schedule, and the willingness to disclose, in writing, the protocol the clinic uses and the data it has accumulated. The Korean Ministry of Health and Welfare's foreign-patient registration framework provides a baseline; the registration number alone is not the credential. What recommends a clinic is the cadence of the consultation that follows the registration. 慢慢嚟, the lab head told me, and one understands the phrase only after sitting through several of these consultations. The slow ones are the trustworthy ones. The room that takes ninety minutes to walk a candidate patient through harvest, processing, expected response, contraindications, and follow-up is the room one chooses, even when the room next door promises a faster appointment and a more confident result.

“BM-MSCs are a clinically established cell preparation with a favourable acute safety profile, an evolving evidence base for several indications, and a marketing language that occasionally outruns the data. The room one returns to is the one that volunteers the limitations as readily as the strengths.”

Liu Mei-Hua, on reading the regenerative consultation

Frequently asked questions

How is a bone marrow MSC procedure different from an adipose SVF procedure?

The two preparations begin in different tissues and travel different processing paths. Bone marrow MSCs are recovered from a small-volume aspirate of the posterior iliac crest under local anaesthesia; adipose SVF is recovered from a small-volume liposuction harvest of the lower abdomen or medial thigh. The cell populations differ — BM is haematopoietic-rich with a smaller mesenchymal fraction, SVF is heterogeneous with multiple stromal and vascular populations — and the typical indications differ. Orthopaedic and immunological indications more often route to BM; aesthetic and dermatological indications more often route to SVF.

Is the iliac crest aspiration painful?

Patients describe a deep, brief, pressure-like sensation during each aspirate rather than pain in the conventional sense, with mild soreness at the harvest site for three to seven days afterward. Local anaesthesia is infiltrated through the skin, subcutaneous tissue, and periosteum; intravenous sedation is offered as a comfort measure rather than a clinical necessity. The recovery is, in practical terms, briefer than most patients anticipate from the consent paperwork.

Should I choose same-session BMAC or culture-expanded BM-MSCs?

The choice is indication-dependent, regulatory, and operator-dependent in roughly that order. BMAC delivers a same-day product with a smaller MSC absolute count; culture expansion delivers a substantially more characterised product with a substantially higher cell count, at the cost of two to four weeks of laboratory processing and a more involved regulatory pathway. A reputable consultation will explain which pathway the clinic uses, why, and what the alternative would entail.

How quickly does an effect appear, and how long does it last?

Patients report initial symptom modification — pain reduction, swelling, range of motion — within four to twelve weeks of injection, with the more characteristic changes accumulating across three to six months. Duration is indication-dependent: orthopaedic responses commonly persist for twelve to twenty-four months in published series, with substantial inter-patient variability. Studies suggest dose, niche, and patient factors all influence the response. A careful consultation discusses the realistic time course before the consent forms are signed.

Are bone marrow MSCs an appropriate option for aesthetic indications?

Sometimes, but adipose-derived approaches are usually the more natural starting point for aesthetic work. The harvest investment for BM is meaningful, and the cell biology fits inflammation-driven and immune-modulated indications more reliably than tissue-volume or dermal-compliance indications. A reputable Seoul consultation will route most aesthetic candidates toward SVF or cultured ADSC and reserve BM-MSCs for the indications in which the harvest is genuinely justified by the disease biology.

What contraindications should I disclose at the consultation?

Active or recent malignancy, uncontrolled autoimmune disease, active infection at the harvest or planned injection site, current pregnancy or lactation, and bleeding disorders or anticoagulant therapy that cannot be safely paused. Diabetes, hypertension, and thyroid conditions are typically not absolute contraindications but warrant a closer pre-procedural workup. A full medication list and recent blood work are baseline; rooms that skip this paperwork are rooms one declines.

Can I combine a BM-MSC procedure with platelet-rich plasma or other adjuncts?

Combination is operator-dependent and indication-dependent. Some protocols pair BM-MSC injection with PRP at the same visit, particularly in orthopaedic indications, where the platelet-derived growth factors are thought to support the paracrine signalling environment the MSCs create. Combination with toxin or filler injection on the exact treatment area is generally deferred by two to four weeks. The sequencing question is the consultation's, not the marketing copy's.